An alternative method for estimating efficacy of the AN1792 vaccine for alzheimer disease

Neurology

Volumn 71, Issue 9, 2008, Pages 697-698

  Grundman, M ^a   Gilman, S ^a   Black, R S ^a   Fox, N C ^a   Koller, M ^a   Chi, Y Y ^a   Ramos, E M ^a   Lee, W W ^a   Kukull, W A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; PLACEBO; ANTIBODY; VACCINE;

ALZHEIMER DISEASE; ANTIBODY TITER; BAYES THEOREM; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNIZATION; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; BRAIN SIZE; NEUROPSYCHOLOGICAL TEST; PROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; ACTIVE IMMUNIZATION; BIOASSAY; BLOOD; IMMUNOLOGY; METHODOLOGY; NOTE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PLACEBO EFFECT; STANDARD; STATISTICAL ANALYSIS;

ALZHEIMER DISEASE; ANTIBODIES; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HUMANS; IMMUNOTHERAPY, ACTIVE; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBO EFFECT; TREATMENT OUTCOME; VACCINES;

EID: 52449086601     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000325484.81127.15     Document Type: Letter

References (4)

1. Koepsell TD, Chi Y-Y, Zhou X-H, Lee WW, Ramos EM, Kukull WA. An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease. Neurology 2007;69:1868-1872.
2. Gilman S, Koller M, Black RS, et al. Clinical effects of A-beta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64: 1553-1562.
3. Fox NC, Black RS, Gilman S, et al. Effects of A-beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64: 1563-1572.
4. Imbens GW, Rubin DB. Bayesian inference for causal effects in randomized experiments with noncompliance. Ann Stat 1997; 25:305-327.